An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease

NCT ID: NCT05899673

Last Updated: 2025-10-14

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 31 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-08-08
• Study Completion Date: 2033-05-02

Brief Summary

The main aim of this study is to learn if fazirsiran is safe during long-term use in people with liver disease caused by the abnormal Z-alpha-1 antitrypsin (Z-AAT) protein. People who have taken part in previous fazirsiran studies (AROAAT2001 [NCT03945292] or AROAAT2002 [NCT03946449]) can continue to receive fazirsiran every 3 months as long as they participate in this study, the study is ongoing or until health authorities in their country approve fazirsiran to be publicly available. The study may also provide information on whether fazirsiran has a long-term effect in reducing liver fibrosis or slowing down the progression of liver fibrosis in people with liver disease due to the abnormal Z-AAT protein.

Conditions

Alpha1-Antitrypsin Deficiency

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Fazirsiran 200 mg

Participants who are currently taking part in or who have completed their treatment in parent studies AROAAT2001 (NCT03945292) and AROAAT2002 (NCT03946449) may rollover in this study to receive fazirsiran, 200 milligrams (mg), injection, subcutaneously on Day 1 and once every 12 weeks (Q12W) thereafter until fazirsiran receives approval and is commercially available in the participant's country, until a participant withdraws from the study or the sponsor decides to terminate the study.

Group Type: EXPERIMENTAL

Fazirsiran Injection

Intervention Type: DRUG

Fazirsiran will be injected subcutaneously.

Interventions

Fazirsiran Injection

Fazirsiran will be injected subcutaneously.

Intervention Type: DRUG

Other Intervention Names

TAK-999; ARO-AAT

Eligibility Criteria

Inclusion Criteria

• Participants must meet all of the following criteria to be eligible for inclusion in the study:
• The participant is willing and able to understand and fully comply with study procedures and requirements, in the opinion of the investigator.
• The participant is able to read, understand, and complete the study questionnaires electronically per investigator's judgment.
• The participant has provided informed consent (ICF) (that is, in writing, documented via a signed and dated ICF) and any required privacy authorization before the initiation of any study procedures.

Note: For participants who comprehend, can provide informed consent, and are unable to sign the ICF, an impartial witness may sign the ICF on behalf of the participant after the participant has orally consented to the participant's participation in the study.

• The participant enrolling in this open-label extension (OLE) study will have participated in a previously qualifying study, and will be considered for eligibility based on the following study-specific criteria:
• AROAAT2001:

• Participants with fibrosis may roll over into this OLE study after they reach their next regularly scheduled, Q12W visit.
• Participants with fibrosis who have completed the AROAAT2001 study may be enrolled into the OLE study.
• AROAAT2002:

• Participants in Cohorts 1 and 1b may roll over after completing the 24-week primary study period.
• Participants in Cohort 2 may roll over after completing the 48-week primary study period.
• Participants who have completed the study may be enrolled into the OLE study.
• The participant is a nonsmoker (defined as: does not smoke cigarettes daily for at least 24 weeks) with current nonsmoking status confirmed by urine cotinine at Day 1.

• E-cigarettes (vapor) are not permitted.
• The participant may be on nicotine replacement (patch or gum). A positive urine cotinine result due to nicotine replacement is acceptable for enrollment at the discretion of the investigator.
• The participant must have suitable venous access for blood sampling.
• It must be confirmed that the participant does not have hepatocellular carcinoma (HCC). Participants will be screened for HCC with alpha-fetoprotein (AFP) and abdominal ultrasound. If the participant has any of the following, they will be required to have contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) imaging to exclude HCC before enrollment.

• AFP >20 nanogram per milliliter (ng/mL).
• AFP 15 to 19 ng/mL at enrollment if that is >2 times prestudy levels (if available).
• Any liver lesion >10 millimeter (mm) (longest diameter) detected by ultrasound.
• Poor visibility of liver on ultrasound.
• A person of childbearing potential (POCBP) must have a negative urine pregnancy test performed within 3 days prior to Day 1 dosing in this study (sensitive to 25 International Unit [IU] human chorionic gonadotropin [hCG]).
• The participant must use appropriate contraception methods (that is, highly effective methods for female and medically appropriate methods for male study participants) for the entire duration of the study. Participants who terminate early must use appropriate contraception methods for 6 months after the last dose of study intervention. Male participants who terminate early must not donate sperm for at least 6 months after the last dose of study intervention.
• Sexual abstinence, for the purposes of this study, is only considered a highly effective method of contraception when considered to align with the preferred and usual lifestyle of the participant. It will be employed for the entire duration of the study and the 6 months after last dose of study intervention.
• Periodic abstinence (calendar, symptothermal, postovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea methods are not considered "true" abstinence and are not acceptable methods of contraception.

Exclusion Criteria

• The participant is likely to require major surgery. Major surgery typically requires at least 1 night in the hospital. Examples include laparoscopic surgery (except cholecystectomy and tubal ligation); Gastrointestinal tract (GI) tract surgery including 1 or more segments of the colon or terminal ileum; open resection of organs; large joint replacements; mastectomy with reconstruction; and spine, thoracic, vascular, or intracranial surgery.
• The participant has evidence of other forms of chronic liver diseases, including viral hepatitis B or C, primary biliary cholangitis, primary sclerosing cholangitis, Wilson disease, alcoholic hepatitis, hemochromatosis, liver cancer, history of biliary diversion, or autoimmune hepatitis.
• The participant has abnormal finding(s) of clinical relevance during the evaluation before the first study dosing that, in the opinion of the investigator, could adversely impact participant safety during the study or adversely impact study results. For US only: Participants with baseline emphysema may be allowed into the OLE if their lung disease has been stable.
• The participant had major protocol deviation(s) in AROAAT2001 or AROAAT2002 that would affect the conduct of this study.
• The participant permanently discontinued investigational product because of an AE, adjudicated as related to the study intervention, in AROAAT2001 or AROAAT2002.
• Female participants who became pregnant during Study AROAAT2001 or AROAAT2002, female participants who are lactating or planning to become pregnant during the study period; or males or female participants of childbearing potential not agreeing to continue using appropriate contraception methods through the conclusion of study participation.
• The participant has a Child-Turcotte-Pugh (CTP) score >=7 OR (Model for End-Stage Liver Disease) MELD score >14.
• Participants who have a newly-diagnosed malignancy or recurrence of malignancy (except for resected cutaneous basal cell carcinoma, squamous cell carcinoma, superficial bladder tumors, or carcinoma in situ of the uterine cervix that has been treated with no evidence of recurrence).
• The participant is experiencing a pulmonary exacerbation at the time of enrollment (participant enrollment may be temporarily delayed after the clinical resolution of an exacerbation).
• The participant has unstable, poorly controlled, or severe hypertension. Participants may be reevaluated once their blood pressure is successfully controlled.
• The participant has a history of more than moderate alcohol consumption within 12 months before the Day 1 visit.
• The participant has a history of hypersensitivity or allergies to fazirsiran or any associated excipients.
• The participant has any concomitant medical or psychiatric condition or social situation that would make it difficult to comply with protocol requirements or put the participant at additional safety risk.
• The participant has a history of clinically significant hematologic, renal, hepatic, cardiovascular, infectious, pulmonary, neurologic, psychiatric, GI, systemic inflammatory, metabolic, or endocrine disorder or any other condition that, in the opinion of the investigator, rendered the participant a poor candidate for inclusion into the study.
• The participant has a history of thromboembolic disease (including deep vein thrombosis or pulmonary embolism), within 24 weeks before enrollment; or is taking chronic anticoagulants. (Note: Participants taking stable doses of chronic anticoagulants may be allowed after consultation with the medical monitor, if they do not have cirrhosis or a history of liver decompensating events).
• The participant is unable to return for all scheduled study visits.
• The participant has known or suspected coronavirus disease 2019 (COVID-19) that in the opinion of the sponsor and investigator does not resolve during screening. Positive antibody testing for COVID-19 without other evidence of current or recent active infection does not exclude participation. Enrollment of participants who fail inclusion due to COVID-19 infection may be temporarily delayed at the discretion of the sponsor and investigator. If the participant has a positive polymerase chain reaction (PCR) with no other evidence of infection, a retest may be allowed; however, to enroll in the study the participant must have a negative PCR.
• The participant is a study site employee, an immediate family member (for example, spouse, parent, child, sibling), or is in a dependent relationship with a study site employee who is involved in conduct of this study, or may consent under duress.
• The participant who, in the opinion of the investigator or the sponsor, will be uncooperative or unable to comply with study procedures.
• The participant who participates in other studies involving an investigational product.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Takeda

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Study Director

Role: STUDY_DIRECTOR

Takeda

Locations

UCSD Altman Clinical and Translational Research Institute

La Jolla, California, United States

Stanford Medicine Outpatient Center

Redwood City, California, United States

UF Clinical and Translational Science Institute

Gainesville, Florida, United States

University Of Iowa Hospitals And Clinics

Iowa City, Iowa, United States

Medical University of South Carolina - Hollings Cancer Center - PPDS

Charleston, South Carolina, United States

Medizinische Universitat Wien (Medical University of Vienna)

Vienna, , Austria

Universitätsklinikum der RWTH Aachen

Aachen, North Rhine-Westphalia, Germany

Hospital Nélio Mendonça

Funchal, , Portugal

Addenbrooke's Hospital

Cambridge, , United Kingdom

Royal Infirmary of Edinburgh - PPDS

Edinburgh, , United Kingdom

Countries

United States; Austria; Germany; Portugal; United Kingdom

Related Links

https://clinicaltrials.takeda.com/study-detail/9e52333653b14cfe?idFilter=%5B%22TAK-999-3003%22%5D

To obtain more information on the study, click here/on this link.

Other Identifiers

2023-503497-21-00

Identifier Type: CTIS

Identifier Source: secondary_id

TAK-999-3003

Identifier Type: -

Identifier Source: org_study_id